Antibody Therapeutics against HIV-1 – Advances and Obstacles
Boris Juelg, MD, Ph.D., Group Leader, Ragon Institute of MGH, MIT and Harvard, Infectious Diseases Division, MGH, CVVR, BIDMC
Boris Juelg, MD, Ph.D., Group Leader, Ragon Institute of MGH, MIT and Harvard, Infectious Diseases Division, MGH, CVVR, BIDMC